BioCentury | Feb 24, 2021
Product Development

Evidence mounts that BCMA CAR T cells are vulnerable to antigen escape

Two papers characterizing cases of resistance to bluebird and BMS’s multiple myeloma CAR T cell therapy point to a vulnerability that could extend to other anti-BCMA therapies — loss of the target’s gene....
BioCentury | Feb 16, 2021
Product Development

Bluebird shares at six-year low following hematologic malignancies in sickle cell trial

Gene therapy company bluebird is temporarily suspending two clinical trials of its sickle cell candidate while it sorts out the causes of two new hematologic malignancies, and has paused marketing of its approved therapy as...
BioCentury | Feb 16, 2021
Finance

Medicxi, blue chip investors launch Centessa with $250M to take asset-centric companies further

Centessa, launched today, is the latest iteration of investors and pharma veterans toying with newco models that could capitalize on the learnings of the last decade and bring greater efficiencies to the conversion of ideas...
BioCentury | Feb 11, 2021
Politics, Policy & Law

Cancer KOLs urge Biden to name Woodcock permanent FDA commissioner

Acting FDA Commissioner Janet Woodcock has picked up a powerful endorsement in a public campaign for President Joe Biden to delete the “acting” part of her title. Nobel laureate James Allison and Mikael Dolsten, CSO...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said Chairman James Mullen will succeed Cynthia Collins as CEO after she steps down on Feb. 15. Collins had held the role since August 2019. Mullen, who was...
BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

Bertrand Bodson, chief digital officer at Novartis AG (NYSE:NVS; SIX:NOVN), will step down from the pharma’s executive committee on Feb. 1. Bodson took on the newly created role at Novartis in January 2018 to integrate new...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

Led by Rick Klausner and Gregory Verdine, LifeMine has found drug candidates with novel mechanisms using its data science platform for mining fungal genomes. The company now has an additional $50 million to move its first programs toward...
BioCentury | Jan 12, 2021
Deals

bluebird’s split could yield two attractive M&A targets

bluebird’s decision to focus on rare diseases and spin out its cancer business by year-end could provide the focus both units need to execute on their pipelines and attract potential partners and buyers.  Nick Leschly,...
BioCentury | Jan 12, 2021
Politics, Policy & Law

COVID accountability, Biden’s bidding & start-up season: a BioCentury podcast

Deals and venture rounds are being unveiled in droves as the J.P. Morgan conference began Monday, but last week’s events in the U.S. capital and the ongoing pandemic have expanded the list of issues to...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...
Items per page:
1 - 10 of 1240
BioCentury | Feb 24, 2021
Product Development

Evidence mounts that BCMA CAR T cells are vulnerable to antigen escape

Two papers characterizing cases of resistance to bluebird and BMS’s multiple myeloma CAR T cell therapy point to a vulnerability that could extend to other anti-BCMA therapies — loss of the target’s gene....
BioCentury | Feb 16, 2021
Product Development

Bluebird shares at six-year low following hematologic malignancies in sickle cell trial

Gene therapy company bluebird is temporarily suspending two clinical trials of its sickle cell candidate while it sorts out the causes of two new hematologic malignancies, and has paused marketing of its approved therapy as...
BioCentury | Feb 16, 2021
Finance

Medicxi, blue chip investors launch Centessa with $250M to take asset-centric companies further

Centessa, launched today, is the latest iteration of investors and pharma veterans toying with newco models that could capitalize on the learnings of the last decade and bring greater efficiencies to the conversion of ideas...
BioCentury | Feb 11, 2021
Politics, Policy & Law

Cancer KOLs urge Biden to name Woodcock permanent FDA commissioner

Acting FDA Commissioner Janet Woodcock has picked up a powerful endorsement in a public campaign for President Joe Biden to delete the “acting” part of her title. Nobel laureate James Allison and Mikael Dolsten, CSO...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said Chairman James Mullen will succeed Cynthia Collins as CEO after she steps down on Feb. 15. Collins had held the role since August 2019. Mullen, who was...
BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

Bertrand Bodson, chief digital officer at Novartis AG (NYSE:NVS; SIX:NOVN), will step down from the pharma’s executive committee on Feb. 1. Bodson took on the newly created role at Novartis in January 2018 to integrate new...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

Led by Rick Klausner and Gregory Verdine, LifeMine has found drug candidates with novel mechanisms using its data science platform for mining fungal genomes. The company now has an additional $50 million to move its first programs toward...
BioCentury | Jan 12, 2021
Deals

bluebird’s split could yield two attractive M&A targets

bluebird’s decision to focus on rare diseases and spin out its cancer business by year-end could provide the focus both units need to execute on their pipelines and attract potential partners and buyers.  Nick Leschly,...
BioCentury | Jan 12, 2021
Politics, Policy & Law

COVID accountability, Biden’s bidding & start-up season: a BioCentury podcast

Deals and venture rounds are being unveiled in droves as the J.P. Morgan conference began Monday, but last week’s events in the U.S. capital and the ongoing pandemic have expanded the list of issues to...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...
Items per page:
1 - 10 of 1240